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Background: Early accurate detection of acute kidney injury (AKI) occurring after cardiac surgery may
improvemorbidity andmortality. Although several novel biomarkers have been developed for the early detection
of AKI, their clinical utility in the critical intraoperative and immediate postoperative period remains unclear.
Study Design: Systematic review and meta-analysis.
Setting & Population: Adult patients having cardiac surgery.
Selection Criteria for Studies: EMBASE, CINAHL, Cochrane Library, Scopus, and PubMed from January
1990 until January 2015 were systematically searched for cohort studies reporting the utility of novel bio-
markers for the early diagnosis of AKI after adult cardiac surgery. Reviewers extracted data for study design,
population, timing of biomarker measurement and AKI occurrence, biomarker performance (area under the
receiver operating characteristic curve [AUROC]), and risk of bias.
Index Tests: Novel urine, plasma, and serum AKI biomarkers, measured intraoperatively and in the early
postoperative period (,24 hours).
Reference Tests: AKI was defined according to the RIFLE, AKIN, or 2012 KDIGO criteria.
Results: We found 28 studies reporting intraoperative and/or early postoperative measurement of urine
(n5 23 studies) or plasma or serum (n5 12 studies) biomarkers. Only 4 of these studies measured bio-
markers intraoperatively. Overall, intraoperative discrimination by the urine biomarkers neutrophil gelatinase-
associated lipocalin (NGAL) and kidney injury marker 1 (KIM-1) demonstrated AUROCs, 0.70, whereas
N-acetyl-b-D-glucosaminidase (NAG) and cystatin C had AUROCs, 0.75. In the immediate 24-hour
postoperative period, the urine biomarkers NGAL (16 studies), KIM-1 (6 studies), and liver-type fatty acid
binding protein (6 studies) exhibited composite AUROCs of 0.69 to 0.72. The composite AUROCs for
postoperative urine cystatin C, NAG, and interleukin 18 were #0.70. Similarly, the composite AUROCs for
postoperative plasma NGAL (6 studies) and cystatin-C (5 studies) were ,0.70.
Limitations: Heterogeneous AKI definitions.
Conclusions: In adults, known urinary, plasma, and serum biomarkers of AKI possess modest discrimi-
nation at best when measured within 24 hours of cardiac surgery.
Am J Kidney Dis. 66(6):993-1005. ª 2015 The Authors. Published by Elsevier Inc. on behalf of the National
Kidney Foundation, Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
INDEX WORDS: Cardiopulmonary bypass; alpha-1-microglobulin (A1M); hepcidin-25; liver-type fatty acid
binding protein (L-FABP); monocyte chemoattractant protein 1 (CCL2); uric acid; tumor necrosis factor
alpha (TNF-a); acute kidney injury; biomarker; intraoperative; early postoperative; diagnostic performance.Acute kidney injury (AKI) is a serious and po-tentially lethal complication of cardiac surgery.
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Ho et alshort-term mortality.3 Even mild AKI, deﬁned as a
25% increase in serum creatinine level over baseline,
is associated with a doubling in long-term mortality
up to 10 years after surgery.4 The negative effect of
AKI is independent of other prognostic factors and
persists even if kidney function recovers to baseline.4
Furthermore, AKI increases the risk for subsequent
chronic kidney disease and kidney failure, with its
associated morbidity and mortality.5
Cardiac surgery–associated AKI results from the
interplay between patient susceptibility to kidney
injury and intraoperative kidney insults. The dominant
mechanism of injury is thought to be intraoperative
ischemia-reperfusion injury. Data from animal studies
show that AKI due to ischemia-reperfusion injury is
potentially reversible,6-10 provided that the therapeutic
intervention is administered at or shortly after the time
of injury, during a window of time corresponding to
the initiation or early extension phases of ischemia-
reperfusion injury.11,12 Currently, the diagnosis of
AKI relies on serum creatinine level, which takes 2 to 3
days to increase above a deﬁned threshold due to the
rate-limiting step of creatinine production and release
by skeletal muscle. Interventions administered at the
time of AKI diagnosis using elevated serum creatinine
level may not be effective, as has been demonstrated in
multiple clinical trials of promising therapies for AKI
in humans.13-15
Accordingly, a biomarker that can detect AKI early
may facilitate intervention within this narrow window
of reversibility. Ideally, such a biomarker would
identify injury as it occurs intraoperatively or at least
within a few hours after surgery. Recent research
efforts have identiﬁed multiple proteins that may pro-
vide the basis for early diagnosis of AKI.16-19 We hy-
pothesized that some of these novel biomarkers could
predict postoperative AKI accurately. We therefore
conducted a systematic review andmeta-analysis of the
diagnostic performance of early urinary, plasma, and
serum biomarkers of cardiac surgery–associated AKI.
METHODS
Design, Search Strategy, and Study Selection
We performed a systematic review of the literature to assess the
association of novel urine, serum, and plasma biomarkers with
the early identiﬁcation of AKI following adult cardiac surgery.
The search strategy was designed and implemented under the
guidance of a medical librarian (K.M.). The following electronic
databases were searched from January 1, 1990, to January 1, 2015:
EMBASE, Cumulative Index to Nursing and Allied Health
Literature (CINAHL), Cochrane Library, Scopus, and PubMed.
The search strategy was tailored to each database and included a
combination of key words and subject headings. Key words used
included AKI, acute kidney injury, kidney failure, kidney disease,
cardiac surgery, prognosis, diagnosis, biomarkers, NGAL,
neutrophil gelatinase associated lipocalin, IL-18, interleukin 18,
KIM1, kidney injury molecule 1, L-FABP, liver fatty acid binding
protein, hepcidin-25, cystatin, cystatins, and HAVCR1. Subject994headings varied by database and included renal insufﬁciency,
predictive value of tests, diagnosis, sensitivity and speciﬁcity,
early diagnosis, and biological markers. Full search strategies are
available in Item S1 (available as online supplementary material).
The search string for each database was tested for rigor by a
manual check for key eligible publications and their listed cita-
tions. There were no language restrictions. Retrieved citations
were downloaded into RefWorks, version 2.0.
Article Eligibility Criteria
Eligibility for full-text review was determined by 2 reviewers
(S.W. and K.G.) based on evaluation of the title and abstract of
each citation. Any article deemed potentially relevant by either
reviewer was retrieved for full-text review. Reference lists of any
relevant review articles were also screened to identify studies that
may have been missed in the database search. Disagreements were
resolved by consensus. Included studies had to be prospective,
have a clearly deﬁned AKI outcome (RIFLE [risk, injury, failure,
loss, and end-stage renal disease]: “risk [R]” or greater; AKIN
[AKI Network]: stage 1 or greater; or KDIGO [Kidney Disease:
Improving Global Outcomes]: creatinine criteria), have an
observed outcome minimum of 10 AKI events, and report the
timing of the biomarker assessment (intraoperative or ,24 hours
postoperatively).
Data Extraction
A Microsoft Excel data extraction form was created to capture
relevant information from included studies (tables a-b of Item S2).
K.G. conducted the extraction with veriﬁcation by S.W. The
following information was extracted for each study: (1) study
characteristics, such as year of publication, study design, study
population, type of biomarker, and sample size; (2) timing of
biomarker measurement; (3) number of documented cases of AKI;
(4) details of AKI deﬁnition; and (5) estimate of the area under the
receiver operating characteristic curve (AUROC) for that
biomarker. In cases for which biomarker AUROC was assessed at
several time points, the measurement showing the best discrimi-
nation within the ﬁrst 24 hours was abstracted.
Reporting Quality and Risk of Bias
We used the QUADAS (Quality Assessment of Diagnostic
Accuracy Studies)-2 tool to assess risk of bias.20 We developed
operational deﬁnitions for high, low, and unclear risk of bias for
each of the 14 QUADAS-2 domains (Table S1). Each study was
then reviewed by C.R. and R.B. and rated as high, low, or unclear
risk of bias for each of the 14 QUADAS-2 domains. Disagree-
ments between reviewers on any item were settled by consensus
between the reviewers. We summarized both individual (Fig S1)
and aggregate (Fig S2) risk of bias data for the included studies.
Statistical Analysis
AUROCs with 95% conﬁdence intervals (CIs) for each
biomarker were extracted and tabulated for each time period re-
ported (intraoperative and postoperative). These data were used to
generate forest plots for each biomarker within each time period of
interest. A random-effects estimate of the composite AUROC with
95% CI was calculated using the Hartung-Knapp-Sidik-Jonkman
method for each biomarker having a minimum of 3 data points.21
Individual study AUROCs were weighted inversely to the size of
their standard errors. Study heterogeneity was assessed using I2 and
the Cochrane Q test; because both were concordant, we report the
I2. In separate sensitivity analyses and when numbers permitted, we
recalculated the biomarker composites after: (1) excluding studies
with fewer than 30 AKI events, (2) stratifying for the AKI deﬁnition
used (AKIN/KDIGO vs RIFLE), (3) stratifying for use of combined
urine output and creatinine criteria versus use of creatinine
criteria alone, and (4) stratifying for early (#6 hours) versus laterAm J Kidney Dis. 2015;66(6):993-1005
AKI Biomarkers in Cardiac Surgery(.6 hours) biomarker sampling in the postoperative period. All
analyses were conducted by a statistician (B.M.H.).
RESULTS
Search Results and Study Selection
The search retrieved 5,035 unique citations for
screening; 265 articles were identiﬁed as potentially
relevant based on title and abstract and were selected
for full-text review. Of these, 28 articles met criteria
for inclusion in the study22-49 (Fig 1; Table S2).
Study Characteristics
Characteristics of the included studies are summa-
rized in Table 1. All 28 studies were published in
English, with 11 originating in North America and the
rest representing an international experience from Asia
and Europe. Sample sizes were greater than 100 for 13
studies. All were prospective observational studies,
with the exception of one that used a randomized
controlled trial cohort.49 The included studies
examined a total of 13 urinary (neutrophil gelatinase-
associated lipocalin [NGAL], cystatin C, N-acetyl-b-
D-glucosaminidase [NAG], kidney injury molecule 1
[KIM-1], interleukin 18 [IL-18], a1-microglobulin,
hepcidin 25, liver-type fatty acid binding protein
[L-FABP], p- and a-glutathione S-transferase (GST),
insulin-like growth factor-binding protein 7 [IGFBP7],
tissue inhibitor of metalloproteinase 2 [TIMP-2], and
hepatocyte growth factor) and 6 plasma or serum
(NGAL, cystatin C, uric acid, monocyte chemo-
attractant protein 1 [MCP-1], plasma free hemoglobin,
and tumor necrosis factor a [TNF-a]) biomarkers. In
this article, we use u-, p-, and s- to indicate urinary,
plasma, and serum biomarkers, respectively. TheNot cardiac surgery or AKI:
Review article:                                        
Conference abstract:                             
No test performance metrics:
Animal study:
Duplicate cohort:
Pediatric study:
No AKI definition:
Fewer than 10 AKI events:
Not prospective cohort:
Unclear biomarker timing:
Preoperative biomarker:
102
50
25
15
10
8
7
6
6
3
1
2
Initial search: 
5035 articles
Excluded based on title/abstract: 
4,772 articles
Potentially relevant:
263 articles
28 studies
Excluded after full-text review:
Figure 1. Selection of articles for review. Abbreviation: AKI,
acute kidney injury.
Am J Kidney Dis. 2015;66(6):993-1005studies encompassed a total of 5,122 participants, of
whom 956 developed AKI. The number of studies
with reportable results for each biomarker is listed in
Table 1. Of these studies, 26 reported diagnostic per-
formance in the early postoperative period, whereas 4
studies reported intraoperative data, deﬁned as the
period after induction of anesthesia to closure of the
thoracic cavity.
Deﬁnition of AKI
Eight studies used the RIFLE; 16, the AKIN; and 3,
the KDIGO criteria for AKI.50 One of the studies used
a combined AKIN/RIFLE scheme (Parikh et al43).
Most studies used a minimal threshold for AKI
(RIFLE R or AKIN 1), whereas 2 studies set higher
thresholds (Liang et al30: RIFLE I; Parikh et al43:
AKI 5 AKIN $ 2 or RIFLE $ I]). Only 7 studies
applied both creatinine and urinary output criteria as
speciﬁed in RIFLE, AKIN, and KDIGO.
Risk of Bias
Using the QUADAS-2 tool, we identiﬁed several
study characteristics that might increase risk of bias
(Figs S1 and S2). Domain 1 of the QUADAS ad-
dresses patient selection and diagnostic spectrum bias.
Although most studies included a general cardiac
surgery population with minimal exclusions, several
studies did not clearly delineate the selection criteria
for the test cohort. Moreover, some studies selected
narrower spectrum populations based on risk of AKI
(Parikh et al43 and Meersch et al47) or type of surgery
(aortic aneurysm [Vermeulen Windsant et al22]; aortic
valve replacement for aortic stenosis [Kidher et al46]).
Test performance derived from those studies may not
be the same as in less selected populations.
Domain 3 addresses aspects of the reference stan-
dard. Incomplete or inconsistent operationalization of
the chosen reference standard for AKI (RIFLE, AKIN,
or KDIGO) was evident in many of the studies. For
example, most studies did not apply the urine output
subcriteria, although this is a speciﬁed component in all
AKI classiﬁcation schemes. Many smaller deviations
were also common: for example, many studies using
AKIN extended the time frame for creatinine level in-
crease from 48 to 72 hours or applied only the absolute
or relative creatinine level increase criteria, but not both.
Finally, in domain 4 (study ﬂow), less than a third of
studies provided an accurate accounting of dropouts,
and less still provided a STROBE (Strengthening the
Reporting of Observational Studies in Epidemiology)
or similar diagram for the study.
Intraoperative Biomarker Measurement
A total of 4 studies reported biomarkers in the intra-
operative period (Table 2). Of these, urinary NGAL and
urinary NAG had only 2 AUROC values reported each,995
Table 1. Characteristics of the 28 Included Studies
Study Country
Period of
Biomarker
Measurement Biomarkers Assessed N
No. of AKI
Events AKI Definition
Urine
Criteria?
Haase23 (2008) AU Postoperative u-IL-18 100 20 RIFLE $ R No
Koyner24 (2008) US Intraoperativea u-cystatin C, p-cystatin C, u-NGAL 72 34 AKIN$ 1 No
Wagener25 (2008) US Postoperative u-NGAL 426 85 AKIN$ 1 No
Haase-Fielitz26
(2009)
AU Postoperative p-NGAL, p-cystatin C 100 23 RIFLE $ R No
Han27 (2009) US Both u-NGAL, u-NAG, u-KIM-1 90 36 AKINa $ 1 No
Liangos28 (2009) US Postoperative u-KIM-1, u-NGAL, u-NAG, u-IL-18,
u-A1M, u-cystatin C
103 13 AKINa $ 1 No
Koyner29 (2010) US Postoperative u-NGAL, u-cystatin C, u-KIM-1,
u-HGF, u-p-GST, u-a-GST
123 46 AKIN$ 1 No
Liang30 (2010) CN Postoperative u-KIM-1, u-IL-18 122 30 RIFLE $ I No
Perry31 (2010) US Both p-NGAL 879 75 RIFLE $ R No
Ristikankare32
(2010)
FI Postoperative p-cystatin C 110 62 RIFLE $ R Yes
Vermeulen
Windsant22 (2010)
NL Intraoperative u-NAG, p-fHb 35 19 AKIN$ 1 Yes
Wald33 (2010) CA/US Postoperative p-cystatin C 150 47 AKINa $ 1 No
Heise34 (2011) DE Postoperative u-NGAL, u-cystatin C, u-A1M 50 38 AKIN$ 1 Yes
Ho35 (2011) CA Postoperative u-hepcidin-25 338 29 RIFLE $ R No
Ejaz36 (2012) US Postoperative u-NGAL, u-IL-18, s-uric acid,
s-MCP-1, s-TNF-a
100 27 AKIN$ 1 No
Katagiri37 (2012) JP Postoperative u-NAG, u-L-FABP 77 28 AKIN$ 1 No
Matsui38 (2012) JP Postoperative u-L-FABP, u-NGAL, u-NAG 85 48 AKIN$ 1 No
Sargentini39 (2012) IT Postoperative u-NGAL 52 15 AKIN$ 1
Liebetrau40 (2013) DE Postoperative u-NGAL, p-cystatin C 141 19 KDIGO Yes
Liu41 (2013) CN Postoperative u-L-FABP, u-NGAL 109 26 AKIN$ 1 No
Munir42 (2013) PK Postoperative u-NGAL 88 11 AKIN$ 1 Yes
Parikh43 (2013) US/CA Postoperative p-NGAL, u-NGAL, u-IL-18,
u-KIM-1, u-L-FABP
1,200 71 RIFLE $ I or
AKIN$ 2
No
Paarmann44 (2013) DE Postoperative p-NGAL, u-NGAL, u-KIM-1,
u-L-FABP
136 29 AKIN$ 1 No
Susantitaphong45
(2013)
US Postoperative u-a-GST, u-p-GST 252 72 AKIN$ 1 No
Kidher46 (2014) UK Postoperative p-NGAL 53 16 RIFLE R Yes
Meersch47 (2014) DE Postoperative u-NGAL, u-TIMP2, u-IGFBP7 50 26 KDIGO Yes
Gaipov48 (2015) TR Postoperative p-NGAL, u-NGAL, s-uric acid 60 20 KDIGO No
Prowle49 (2015) AU Postoperative u-a-GST, u-p-GST, u-NGAL,
u-hepcidin, s-cystatin C
93 25 RIFLE $ R No
Note: Design of all 28 studies was prospective cohort.
Abbreviations: A1M, a1-microglobulin; AKI, acute kidney injury; AKIN, Acute Kidney Injury Network; AU, Australia; CA, Canada; CN,
China; DE, Germany; fHb, free hemoglobin; FI, Finland; GST, glutathione S-transferase; HGF, hepatocyte growth factor; IGFBP,
insulin-like growth factor-binding protein; IL, interleukin; IT, Italy; JP, Japan; KDIGO, Kidney Disease: Improving Global Outcomes;
KIM, kidney injury molecule; L-FABP, liver-type fatty acid binding protein; MCP, monocyte chemoattractant protein; NAG, N-acetyl-b-D-
glucosaminidase; NGAL, neutrophil gelatinase-associated lipocalin; NL, Netherlands; p-, plasma; PK, Pakistan; R, risk; RIFLE, risk,
injury, failure, loss, end-stage renal disease; s-, serum; TIMP, tissue inhibitor of metalloproteinase; TNF, tumor necrosis factor; u-,
urine; TR, Turkey; UK, United Kingdom; US, United States.
aA $ 50% or $0.3 mg/dL in serum creatinine level from the preoperative value during the first 3 days.
Ho et alwhich was insufﬁcient to allow calculation of a mean-
ingful composite measure. One of the NAG studies did
not report the 95% CI for the AUROC. Overall,
u-NGAL and u-KIM-1 had AUROCs, 0.7, whereas
u-NAG and u-cystatin C had AUROCs, 0.75.
Postoperative Biomarker Measurement
Twenty-six studies reported the early postoperative
diagnostic performance of urinary and/or plasma/
serum biomarkers (Table 3). Of these, calculation of a996meaningful composite AUROC was possible for 8
urinary and 2 plasma biomarkers (Fig 2). u-NGAL (16
studies), u-KIM-1 (6 studies), and u-L-FABP (6
studies) exhibited composite AUROCs of 0.72. The
compositeAUROCs for u-cystatin C, u-NAG, u-IL-18,
u-a-GST, and u-p-GST were all ,0.7 (range,
0.57-0.69). A composite AUROC was not calculated
for u-hepcidin (2 studies; AUROCs, 0.73 and 0.77),
u-a1-microglobulin (2 studies; AUROCs, 0.61 and
0.62), the product of u-TIMP-2 and u-IGFBP7Am J Kidney Dis. 2015;66(6):993-1005
Table 2. Intraoperative AKI Biomarker Performance
Biomarker Study Sample Collection Time N No. of AKI Events AUROC (95% CI)
Urine
NGAL Han27 (2009) Immediately after CPB 90 36 0.59 (0.48-0.69)
Koyner24 (2008) Immediately after CPB 72 34 0.61 (0.46-0.75)
Cystatin C Koyner24 (2008) Immediately after CPB 72 34 0.71 (0.57-0.84)
NAG Vermeulen Windsant22 (2010) After 15-min reperfusion 35 19 0.76 (NR)
Han27 (2009) Immediately after CPB 90 36 0.61 (0.50-0.71)
KIM-1 Han27 (2009) Immediately after CPB 90 36 0.68 (0.58-0.78)
Plasma
NGAL Perry31 (2010) Immediately after CPB 879 75 0.64 (0.58-0.71)
Cystatin C Koyner24 (2008) Immediately after CPB 72 34 0.63 (0.48-0.78)
fHb Vermeulen Windsant22 (2010) Peak intraoperative 35 19 0.73 (NR)
Abbreviations: AKI, acute kidney injury; AUROC, area under the receiver operating characteristic curve; CI, confidence interval;
CPB, cardiopulmonary bypass; fHb, free hemoglobin; KIM, kidney injury molecule; NAG, N-acetyl-b-D-glucosaminidase; NGAL,
neutrophil gelatinase-associated lipocalin; NR, not reported.
AKI Biomarkers in Cardiac Surgeryconcentrations (1 study; AUROC, 0.81), and u-hepa-
tocyte growth factor (1 study; AUROC, 0.67).
Two plasma biomarkers were meta-analyzed, and
both p-NGAL (6 studies) and p-cystatin C (5 studies)
had composite AUROCs , 0.75 (Fig 3). A single
small study reported individual AUROCs for s-uric
acid (0.77), s-TNF-a (0.76), and s-MCP-1 (0.66),
respectively (Table 3).
Heterogeneity Testing and Sensitivity Analyses
Between-study heterogeneity was visually apparent
on forest plots and tables for most biomarkers and
was statistically signiﬁcant for u-NGAL (I25 81.1%;
P, 0.001), u-KIM-1 (I25 84.0%; P, 0.001), u-IL-
18 (I25 59.1%;P5 0.04), and u-L-FABP (I25 83.8%;
P, 0.001).
We performed several sensitivity analyses to see
whether we could identify sources of this heterogeneity
(Tables 4-6). First, we examined whether event rate
might inﬂuence AUROC estimates by excluding all
studies with fewer than 30 AKI events. In general, the
composite AUROCs were similar after exclusion of
low-event-rate studies. Second, we examined whether
inclusion of urine output criteria in the classiﬁcation of
AKI had any bearing on test performance. This was
possible only for u-NGAL, for which sufﬁcient
numbers of studies with and without urine output
criteria were available. A clear difference was noted in
measured test performance: the AUROC with urine
criteria applied was 0.85 (95% CI, 0.62-1.00) versus
0.69 (95% CI, 0.64-0.75) without, suggesting that this
may be an important source of variability in apparent
test performance. The choice of deﬁnition of AKI may
also contribute to variability in the estimates.Again, due
to the paucity of data points, it was possible to directly
compare deﬁnitions only for u-NGAL. Performance of
u-NGAL was higher in studies using KDIGO versus
AKIN. Moreover, when studies using AKIN wereAm J Kidney Dis. 2015;66(6):993-1005excluded, the performance of p-NGALand p-cystatin C
appeared modestly higher (Table 5). Finally, we
examined whether timing of the urine or plasma
biomarker sample affected test performance estimates.
Both u- and p-NGAL appeared to perform better earlier
than later (Table 6). u-KIM-1 performed slightly worse
when a study with late sampling (.6 hours) was
excluded. u-IL-18 performance did not change when a
study with early sampling (#6 hours) was excluded.
Plasma cystatin performance was slightly less when a
late sampling study was excluded. u-L-FABP and u-p-
and u-a-GST performance did not appear affected
by exclusion of studies sampling after 6 hours.
DISCUSSION
Our meta-analysis of biomarkers in the early detec-
tion of AKI following cardiac surgery has 2 important
ﬁndings. First, we found that current biomarkers have
generally poor and at best moderate discrimination for
AKI when measured within the ﬁrst 24 hours after
cardiac surgery in adults. Second, at present, there are
comparatively few data for the discrimination of these
biomarkers in the intraoperative period, a time of po-
tential active management to mitigate kidney injury.
Only u-NGAL has been studied more than once, but its
intraoperative diagnostic performancewas limited. Our
ﬁndings highlight the need for further investigation into
the early detection of cardiac surgery–associated AKI,
particularly given the need for early prevention and
treatment of this prescheduled ischemia-reperfusion
injury event.
Several other published systematic reviews have
examined the performance of selected biomarkers for
early diagnosis of AKI in a variety of clinical settings
(eg, cardiac surgery, intensive care unit, and after
coronary angiography) and age groups (ie, children vs
adults).19,50-55 These reviews have addressed multiple
biomarkers,50 NGAL,19,51 cystatin C,52 IL-18,53997
Table 3. Postoperative AKI Biomarker Performance
Biomarker Study
Sample
Collection
Time
(h postop) N
No. of AKI
Events AUROC (95% CI) AKI Definition
Urine
Criteria?
Urine
u-NGAL Wagener25 (2008) 18 426 85 0.61 (0.54-0.68) AKIN$ 1 No
Liangos28 (2009) 0 103 13 0.50 (0.33-0.68) AKIN$ 1 No
Han27 (2009) 18 90 36 0.70 (0.59-0.80) AKIN$ 1 No
Koyner29 (2010) 6 123 46 0.72 (0.61-0.83) AKIN$ 1 No
Heise34 (2011) 6 50 38 0.73 (0.63-0.88) AKIN$ 1 ?
Ejaz36 (2012) 24 100 27 0.62 (0.49-0.75) AKIN$ 1 No
Matsui38 (2012) 24 85 48 0.77 (0.63-0.85) AKIN$ 1 No
Sargentini39 (2012) 4 52 15 0.70 (0.56-0.85) AKIN$ 1 No
Liebetrau40 (2013) 4 141 19 0.90 (0.81-0.99) KDIGO Yes
Liu41 (2013) 2 109 26 0.87 (0.78-0.97) AKIN$ 1 No
Munir42 (2013) 4 88 11 0.91 (0.83-0.96) AKIN$ 1 Yes
Paarmann44 (2013) 6 136 29 0.60 (0.48-0.72) AKIN$ 1 No
Parikh43 (2013) 6 1,200 71 0.67 (0.59-0.76) RIFLE $ I or AKIN$ 2 No
Meersch47 (2014) 4 50 26 0.68 (0.53-0.84) KDIGO Yes
Gaipov48 (2015) 24 60 40 0.77 (0.64-0.87) KDIGO No
Prowle49 (2015) 0 93 25 0.73 (0.60-0.86) RIFLE $ R No
Composite 2,906 555 0.72 (0.66-0.79) I2 5 81.1%; P , 0.001
u-cystatin C Liangos28 (2009) 0 103 13 0.50 (0.27-0.72) AKIN$ 1 No
Koyner29 (2010) 12 123 46 0.72 (0.61-0.83) AKIN$ 1 No
Heise34 (2011) 0 50 38 0.59 (0.43-0.73) AKIN$ 1 ?
Composite 276 97 0.63 (0.37-0.89) I2 5 48.4%; P5 0.1
u-NAG Liangos28 (2009) 0 103 13 0.62 (0.41-0.83) AKIN$ 1 No
Han27 (2009) 18 90 36 0.64 (0.52-0.74) AKIN$ 1 No
Katagiri37 (2012) 4 77 28 0.75 (0.60-0.86) AKIN$ 1 No
Matsui38 (2012) 24 85 48 0.73 (0.62-0.84) AKIN$ 1 No
Composite 355 125 0.69 (0.60-0.79) I2 5 0.0%; P 5 0.5
u-KIM-1 Liangos28 (2009) 0 103 13 0.78 (0.64-0.91) AKIN$ 1 No
Han27 (2009) 3 90 36 0.65 (0.54-0.75) AKIN$ 1 No
Koyner29 (2010) 0-6 123 46 0.69 (0.58-0.80) AKIN$ 1 No
Liang30 (2010) 12 122 30 0.88 (0.81-0.93) RIFLE $ I No
Paarmann44 (2013) 6 136 29 0.60 (0.48-0.72) AKIN$ 1 No
Parikh43 (2013) 6 1,200 71 0.71 (0.63-0.78) RIFLE $ I or AKIN$ 2 No
Composite 1,774 225 0.72 (0.59-0.84) I2 5 84.0%; P , 0.001
u-IL-18 Haase23 (2008) 24 100 20 0.55 (0.40-0.71) RIFLE $ R No
Liangos28 (2009) 0 103 13 0.66 (0.49-0.83) AKIN$ 1 No
Liang30 (2010) 12 122 30 0.62 (0.52-0.70) RIFLE $ I No
Ejaz36 (2012) 24 100 27 0.65 (0.52-0.78) AKIN$ 1 No
Parikh43 (2013) 6-12 1,200 71 0.75 (0.69-0.81) RIFLE $ I or AKIN$ 2 No
Composite 1,625 161 0.66 (0.56-0.76) I2 5 59.1%; P 5 0.04
u-A1M Liangos28 (2009) 0 103 13 0.62 (0.47-0.76) AKIN$ 1 No
Heise34 (2011) 0 50 38 0.61 (0.46-0.75) AKIN$ 1 ?
u-Hepcidin Ho35 (2011) 24 338 29 0.73 (0.64-0.84) RIFLE $ R No
Prowle49 (2015) 24 93 25 0.77 (0.67-0.86) RIFLE $ R No
u-L-FABP Katagiri37 (2012) 12 77 28 0.76 (0.62-0.86) AKIN$ 1 No
Liu41 (2013) 2 109 26 0.83 (0.74-0.92) AKIN$ 1 No
Matsui38 (2012) 3 85 48 0.85 (0.77-0.91) AKIN$ 1 No
Paarmann44 (2013) 0 136 29 0.52 (0.40-0.64) AKIN$ 1 No
Parikh43 (2013) 6-12 1,200 71 0.66 (0.58-0.74) RIFLE $ I or AKIN$ 2 No
Prowle49 (2015) 0 93 25 0.69 (0.57-0.81) RIFLE $ R No
Composite 1,700 227 0.72 (0.60-0.85) I2 5 83.8%; P , 0.001
u-a-GST Koyner29 (2010) 0-6 123 46 0.64 (0.52-0.76) AKIN$ 1 No
Susantitaphong45 (2013) 2 242 72 0.56 (0.48-0.64) AKIN$ 1 No
Prowle49 (2015) 0 93 25 0.60 (0.46-0.74) RIFLE $ R No
Composite 458 143 0.57 (0.46-0.68) I2 5 0.0%; P 5 0.5
(Continued)
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Table 3 (Cont’d). Postoperative AKI Biomarker Performance
Biomarker Study
Sample
Collection
Time
(h postop) N
No. of AKI
Events AUROC (95% CI) AKI Definition
Urine
Criteria?
u-p-GST Koyner29 (2010) 0-6 123 46 0.60 (0.48-0.72) AKIN$ 1 No
Susantitaphong45 (2013) 2 242 72 0.62 (0.54-0.70) AKIN$ 1 No
Prowle49 (2015) 0 93 25 0.75 (0.63-0.88) RIFLE $ R No
Composite 458 143 0.65 (0.48-0.82) I2 5 44.8%; P5 0.2
[u-TIMP-2] 3 [u-IGFBP7] Meersch47 (2014) 4 50 26 0.81 (0.68-0.93) KDIGO Yes
u-HGF Koyner29 (2010) 0-6 123 46 0.67 (0.45-0.88) AKIN$ 1 No
Plasma or Serum
p-NGAL Haase-Fielitz26 (2009) 0 100 23 0.73 (0.56-0.88) RIFLE $ R No
Perry31 (2010) 24 879 75 0.67 (0.60-0.74) RIFLE $ R No
Paarmann44 (2013) 6 136 29 0.62 (0.50-0.74) AKIN$ 1 No
Parikh43 (2013) 24 1,200 71 0.70 (0.62-0.78) RIFLE $ I or AKIN$ 2 No
Kidher46 (2014) 3 53 16 0.83 (0.70-0.95) RIFLE R Yes
Gaipov48 (2015) 24 60 40 0.75 (0.62-0.85) KDIGO No
Composite 2,428 254 0.71 (0.64-0.77) I2 5 32.6%; P5 0.2
p-cystatin C Haase-Fielitz26 (2009) 0 100 23 0.75 (0.59-0.90) RIFLE $ R No
Wald33 (2010) 0 150 47 0.68 (0.58-0.78) AKIN$ 1 No
Ristikankare32 (2010) 15-18 110 62 0.71 (0.61-0.81) RIFLE $ R Yes
Liebetrau40 (2013) 4 141 19 0.76 (0.65-0.94) KDIGO Yes
Prowle49 (2015) 0 93 25 0.72 (0.59-0.85) RIFLE $ R No
Composite 594 176 0.69 (0.63-0.74) I2 5 0.0%; P 5 0.9
s-uric acid Ejaz36 (2012) 24 100 27 0.77 (0.66-0.88) AKIN$ 1 No
Gaipov48 (2015) 24 60 40 0.86 (0.74-0.94) KDIGO No
s-MCP-1 Ejaz36 (2012) 24 100 27 0.66 (0.53-0.78) AKIN$ 1 No
s-TNF-a Ejaz36 (2012) 24 100 27 0.76 (0.65-0.87) AKIN$ 1 No
Abbreviations and definitions: ?, unclear; AKI, acute kidney injury; AKIN, Acute Kidney Injury Network; A1M, a1-microglobulin;
AUROC, area under the receiver operating characteristic curve; CI, confidence interval; fHb, free hemoglobin; GST, glutathione S-
transferase; HGF, hepatocyte growth factor; IL, interleukin; KDIGO, Kidney Disease: Improving Global Outcomes; KIM, kidney injury
molecule; L-FABP, liver-type fatty acid binding protein; MCP, monocyte chemoattractant protein; NAG, N-acetyl-b-D-glucosaminidase;
NGAL, neutrophil gelatinase-associated lipocalin; p-, plasma; R, risk; RIFLE, risk, injury, failure, loss, end-stage renal disease; s-,
serum; TNF, tumor necrosis factor; u-, urine; u-[TIMP-2] 3 u-[IGFBP7], product of the urinary concentrations of tissue inhibitor of
metalloproteinase 2 and insulin-like growth factor-binding protein 7.
AKI Biomarkers in Cardiac SurgeryL-FABP,54 and KIM-1.56 Our analysis distinguishes
itself from prior studies by its focus on a single clinical
setting (cardiac surgery), age group (adults only), and
outcome (AKI in the postoperative period). In addi-
tion, we were able to incorporate new studies of known
biomarkers, as well as summarize performance of
several newer biomarkers (ie, MCP-1, TNF-a, uric
acid, p- and a-GST, TIMP-2, and u-IGFBP7).
Our compositeAUROCestimates forNGAL,KIM-1,
cystatinC, and IL-18 are lower than the pooled estimates
reported in other systematic reviews. These differences
most likely relate to important differences in the study
populations included. First, in most cases, previous
meta-analyses included pediatric studies and pooled
biomarker test performance across studies in children
and adults, whereas we excluded studies in children.
Because several biomarkers appear to perform better in
children, inclusion of studies of children would have
improved the pooled performance estimates in thoseAm J Kidney Dis. 2015;66(6):993-1005studies. For example, both NGAL in the review by
Haase et al51 and IL-18 in the review by Liu et al54 were
shown in sensitivity analyses to performbetter in studies
of children than in studies of adults. It must be noted
that this may not be true of all biomarkers because better
performance in child populations was not seen for
KIM-1.55 Second, prior reviews also included and
pooled studies in a variety of clinical settings, not just
cardiac surgery as in our review,whichmay have further
contributed to the differences in pooled estimates.
Finally, our analysis included newer studies, some of
which observed lower discrimination for a given
biomarker. As a result of these differences, our pooled
estimates may more closely reﬂect biomarker perfor-
mance in adults undergoing cardiac surgery.
As with the other systematic reviews, AKI deﬁni-
tion was an important source of heterogeneity in our
study. We sought to minimize this heterogeneity by
requiring included studies to adhere to a validated AKI999
Figure 2. Forest plot of individual and composite areas under the receiver operating characteristic (ROC) curve (AUROCs) for
all postoperative urinary biomarkers with more than 3 included studies. Abbreviations: CI, confidence interval; GST, glutathione
S-transferase; IL, interleukin;KIM, kidney injurymolecule;L-FABP, liver-type fatty acidbindingprotein;NAG,N-acetyl-b-D-glucosaminidase;
NGAL, neutrophil gelatinase-associated lipocalin; u-, urinary.
Ho et alclassiﬁcation scheme. Even so, most studies deviated
from these criteria. The most frequent deviation was
ignoring the urinary criteria altogether. Although a
debate on the validity of urinary criteria for AKI is
beyond the scope of this study, variable adherence to
AKI criteria can lead to signiﬁcant differences in es-
timates of test discrimination, as was observed for
u-NGAL in our analysis.1000It is relevant to contrast the performance of bio-
markers with that of clinical AKI risk prediction
models. To date, 3 independently validated models
have been developed to predict renal replacement
therapy after cardiac surgery.2,57,58 Of these, the
Thakar score has gained the widest acceptance, hav-
ing demonstrated good to excellent discrimination in
both the original derivation and validation cohortsAm J Kidney Dis. 2015;66(6):993-1005
Figure 3. Forest plot of individual and composite areas under the receiver operating characteristic (ROC) curve (AUROCs) for all
postoperative plasma or serum biomarkers with more than 3 included studies. Abbreviations: CI, confidence interval; NGAL, neutrophil
gelatinase-associated lipocalin; p-, plasma.
AKI Biomarkers in Cardiac Surgery(AUROCs of 0.81 vs 0.82, respectively) and in later
independent validation studies (AUROCs of 0.86 and
0.82, respectively, for AKI requiring dialysis).59,60
These AUROCS are signiﬁcantly higher than those
estimated for urine and blood biomarkers in our meta-
analysis. However, it is important to clarify thatTable 4. Sensitivity Analyses Showing Recalculated Composite AUR
Urine Output And Serum Cre
Biomarker
All Studies
Exclu
,
Composite AUROC
(95% CI) No. of Studies
Composite A
(95% C
Urine
NGAL 0.72 (0.66-0.79) 16 0.70 (0.64
Cystatin C 0.63 (0.37-0.89) 3 —
NAG 0.69 (0.60-0.79) 4 —
KIM-1 0.72 (0.59-0.84) 6 0.73 (0.53
IL-18 0.66 (0.56-0.76) 5 —
L-FABP 0.72 (0.60-0.85) 6 —
a-GST 0.57 (0.46-0.68) 3 —
p-GST 0.65 (0.48-0.82) 3 —
Plasma
NGAL 0.71 (0.64-0.77) 6 0.69 (0.60
Cystatin C 0.69 (0.63-0.74) 5 —
Note: Low event count defined as fewer than 30 AKI events.
Abbreviations: AKI, acute kidney injury; AUROC, area under the
GST, glutathione S-transferase; IL, interleukin; KIM, kidney injury m
acetyl-b-D-glucosaminidase; NGAL, neutrophil gelatinase-associated
aOr unknown urine criteria.
Am J Kidney Dis. 2015;66(6):993-1005clinical AKI models were derived to predict severe
AKI requiring dialysis and so are not directly com-
parable to the studies included in our systematic
review, which examined less severe forms of AKI.
Only 2 studies examined the discrimination of bio-
markers for moderate to severe AKI,30,43 so it was notOC When Studies With Low Event Count or Applying Combined
atinine Criteria Included
ding Studies With
30 AKI Events
Excluding all Studies With Urine
Criteria Applieda
UROC
I) No. of Studies
Composite AUROC
(95% CI) No. of Studies
-0.76) 7 0.69 (0.64-0.75) 12
— — —
— 0.69 (0.60-0.79) 4
-0.93) 4 0.72 (0.59-0.84) 6
— 0.66 (0.56-0.76) 5
— 0.72 (0.60-0.85) 6
— 0.57 (0.46-0.68) 3
— 0.65 (0.48-0.82) 3
-0.78) 3 0.68 (0.63-0.74) 5
— 0.66 (0.50-0.82) 3
receiver operating characteristic curve; CI, confidence interval;
olecule; L-FABP, liver-type fatty acid binding protein; NAG, N-
lipocalin.
1001
Table 5. Sensitivity Analyses Showing Recalculated Composite AUROC When Only Studies Using AKIN, RIFLE, or KDIGO
Definitions Included
Biomarker
AKIN-Only Definition RIFLE-Only Definition KDIGO-Only Definition
Composite AUROC
(95% CI) No. of Studies
Composite AUROC
(95% CI) No. of Studies
Composite AUROC
(95% CI) No. of Studies
Urine
NGAL 0.71 (0.62-0.80) 11 — — 0.79 (0.52-1.00) 3
Cystatin C 0.63 (0.37-0.89) 3 — — — —
NAG 0.69 (0.60-0.79) 4 — — — —
KIM-1 0.67 (0.56-0.78) 4 — — — —
IL-18 — — — — — —
L-FABP 0.75 (0.53-0.97) 4 — — — —
a-GST — — — — — —
p-GST — — — — — —
Plasma
NGAL — — 0.73 (0.53-0.94) 3 — —
Cystatin C — — 0.73 (0.67-0.80) 3 — —
Abbreviations: AKI, acute kidney injury; AKIN, Acute Kidney Injury Network; AUROC, area under the receiver operating charac-
teristic curve; CI, confidence interval; GST, glutathione S-transferase; IL, interleukin; KDIGO, Kidney Disease: Improving Global
Outcomes; KIM, kidney injury molecule; L-FABP, liver-type fatty acid binding protein; NAG, N-acetyl-b-D-glucosaminidase; NGAL,
neutrophil gelatinase-associated lipocalin; RIFLE, risk, injury, failure, loss, end-stage renal disease.
Ho et alpossible to determine whether newer biomarkers
might better predict severe AKI. Moreover, even in
the large Translational Research Investigating Bio-
marker Endpoints in AKI (TRIBE-AKI) study,43
only 15 patients needed dialysis. Thus, the lack of
studies large enough to address this question (ie, can
biomarkers accurately diagnose severe AKI) reﬂects
an important knowledge gap.
There are a number of clinical and research impli-
cations to ourﬁndings.Despite the growing availability
of rapid point-of-care tests for many biomarkers, the
current evidence does not support their routine clinical
use for early prediction of AKI after cardiac surgery inTable 6. Sensitivity Analyses Showing Recalculated Composite AU
Earlier Vers
Biomarker
All Studies Ea
Composite AUROC
(95% CI) No. of Studies
Composite A
(95% C
Urine
NGAL 0.72 (0.66-0.79) 16 0.74 (0.65
Cystatin C 0.63 (0.37-0.89) 3 —
NAG 0.69 (0.60-0.79) 4 —
KIM-1 0.72 (0.59-0.84) 6 0.68 (0.61
IL-18 0.66 (0.56-0.76) 5 —
L-FABP 0.72 (0.60-0.85) 6 0.73 (0.50
a-GST 0.57 (0.46-0.68) 3 0.57 (0.46
p-GST 0.65 (0.48-0.82) 3 0.65 (0.48
Plasma
NGAL 0.71 (0.64-0.77) 6 0.73 (0.44
Cystatin C 0.69 (0.63-0.74) 5 0.65 (0.51
Abbreviations:AUROC,areaunder the receiver operating characteri
IL, interleukin; KIM, kidney injury molecule; L-FABP, liver-type fatty a
neutrophil gelatinase-associated lipocalin.
1002adults. No biomarker studied to date appears to have
adequate levels of discrimination for this purpose.
From a research perspective, the paucity of biomarker
data in the intraoperative and very early postoperative
period needs to be addressed because kidney injury is
most likely to be reversible shortly after the renal insult.
Efforts to identify newer biomarkers or novel ways to
use known biomarkers are urgently needed. Moreover,
large studies are needed to examine the ability of bio-
markers to diagnose severe AKI. Finally, robust clin-
ical prediction models integrating newer biomarkers
and clinical variables need to be developed and vali-
dated prior to widespread clinical use. In this context,ROC When Studies Restricted to Those Measuring Biomarkers
us Later
rlier: #6 Hours Later: .6 Hours
UROC
I) No. of Studies
Composite AUROC
(95% CI) No. of Studies
-0.83) 11 0.69 (0.59-0.79) 5
— — —
— — —
-0.75) 5 — —
— 0.66 (0.51-0.80) 4
-0.96) 4 — —
-0.68) 3 — —
-0.82) 3 — —
-1.00) 3 0.69 (0.60-0.78) 3
-0.79) 4 — —
stic curve;CI, confidence interval;GST, glutathioneS-transferase;
cid binding protein; NAG, N-acetyl-b-D-glucosaminidase; NGAL,
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AKI Biomarkers in Cardiac Surgerybecause variation in choice and application of reference
AKI criteria can lead to differences in estimates of test
performance, it is important that future studies use
consistent and carefully applied AKI criteria, prefer-
ably focusing on the more severe and clinically sig-
niﬁcant manifestations of AKI.
Our review has several strengths. First, our search
strategy included several electronic databases to maxi-
mize the chance of capturing all relevant published
literature. In addition, we manually searched the bibli-
ographies of included articles to ensure the sensitivity of
our search strategy. Our inclusion criteria were focused:
only prospective studies with a validated outcome
(AKI) deﬁnition and clear timing of biomarker assess-
ment in relation to AKI were included. Given the clin-
ical goal of reliable AKI recognition in the early
postoperative period to facilitate potential treatment,
we focused on test performance of biomarker mea-
surement within 24 hours postoperatively.
Our study also has limitations. Our review ad-
dressed only the question of early diagnosis of AKI in
the setting of adult cardiac surgery. We cannot
comment on biomarker performance for preoperative
risk stratiﬁcation, in prediction of long-term outcomes,
or in other clinical AKI settings such as pediatric heart
surgery. We included only published literature in this
analysis. Although the direction and magnitude of this
publication bias is unknown, it is probable that the
majority of unpublished studies were negative (ie,
showed weaker discrimination for AKI). Our com-
posite AUROCs based on only published studies may
therefore represent an optimistic estimate. In studies
with serial biomarker measurements, we selected the
most favorable time point (ie, the best AUROC), and
this may also overestimate test performance. Similar to
other systematic reviews, we reported and meta-
analyzed only the raw univariate AUROC. This was
necessary because studies either did not adjust for
clinical AKI risk factors or varied widely in the choice
of variables used for adjustment, precluding mean-
ingful combination of adjusted measures of test
discrimination. It follows that we cannot conclude
from this analysis whether a combination of clinical
variables and selected biomarkers together could
create a highly discriminatory predictive model or
“test” for AKI. Finally, the majority of studies
measured AKI with serum creatinine level, which is
known to be a ﬂawed gold standard. Misclassiﬁcation
of AKI status based on this ﬂawed gold standard could
have diminished the apparent discrimination of the
biomarkers studied.
In conclusion, current biomarkers exhibit at best
modest discrimination for cardiac surgery–associated
AKI in the early postoperative period in adults.
Intraoperatively, only NGAL has been studied to any
extent, and its performance is poor. Ongoing efforts toAm J Kidney Dis. 2015;66(6):993-1005develop new tests for early diagnosis of cardiac sur-
gery associated AKI in adults are still needed.
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